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Abstract: Moderate consumption of wine seems to produce positive health effects derived 
from the occurrence of bioactive polyphenols. The gut microbiota is involved in the 
metabolism of phenolic compounds, and these compounds and/or their metabolites may 
modulate gut microbiota through the stimulation of the growth of beneficial bacteria and the 
inhibition of pathogenic bacteria. The characterization of bacterial metabolites derived from 
polyphenols is essential in order to understand their effects, including microbial modulation, 
and therefore to associate dietary intake with particular health effects. This review aims to 
summarize the current information about the two-way “wine polyphenols–gut microbiota” 
interaction, from a perspective based on the experimental and analytical designs used.  
The availability of advanced methods for monitoring bacterial communities, along with the 
combination of in vitro and in vivo models, could help to assess the metabolism of 
polyphenols in the human body and to monitor total bacterial communities, and, therefore, 
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to elucidate the implications of diet on the modulation of microbiota for delivering 
health benefits. 
Keywords: wine; polyphenols; gut microbiota; probiotics; modulation; batch culture 
fermentation; gastrointestinal simulators; animal models; human studies 
 
1. Introduction 
Wine is considered to be a high bioactive polyphenol content source. Many studies have revealed the 
key role played by phenolic compounds from grapes and wine on human health; cardiovascular diseases 
being the pathologies that have received much attention [1,2]. 
Several studies confirm the importance of the intestinal microbiota to the health of the host, including 
mental health [3]. Gut bacteria not only help to maximize the absorption of nutrients and energy, but 
also are essential in the body’s defense mechanisms [4]. Although polyphenol metabolism starts in the 
mouth and proceeds along the gastrointestinal tract, most of the dietary polyphenols reach the colon, 
where they are subjected to the action of the gut microbiota, thus releasing aglycones that might, to a 
certain extent, be absorbed and degraded to simpler phenolic derivatives and other metabolites which 
could present higher activity at a physiological level than the corresponding food precursors [5].  
These metabolites could also be absorbed, increasing polyphenol bioavailability [6]. Non-absorbed 
polyphenols and/or the resultant phenolic metabolites could affect the growth of gut microbiota,  
thereby modifying their diversity and metabolic activity. In fact, modulation of gut microbiota by 
polyphenols has been a topic that has gained increasing attention from the scientific community in recent 
years, as can be seen from several reviews [7–12]. Among the major wine phenolic compounds that may 
reach the gut, special attention has been given to polymeric flavan-3-ols or proanthocyanidins (also 
known as condensed tannins) since there is evidence that these polyphenols promote the growth of 
beneficial bacteria and the inhibition of pathogenic bacteria while they are extensively metabolized by 
gut microbiota to produce a great range of active metabolites. As relevant reference, an intervention 
study of cocoa flavan-3-ols in healthy volunteers has shown that they enhance the growth of 
Lactobacillus spp. and Bifidobacterium spp. and limit the growth of the Clostridium histolyticum  
group [13]. On the other hand, proanthocyanidins have been found to be largely metabolized into 
phenylvalerolactones and phenolic acids after cocoa intake in humans and rats [14]. 
The aim of this review was to summarize the information available on the action of gut microbiota 
on wine polyphenols (metabolism), as well as the effect of phenolic compounds on the growth of gut 
bacteria (modulation). This two-way polyphenols–gut microbiota interaction will be assessed from a 
perspective based on the experimental designs used, from isolated cultures to omic approaches in the 
case of microbiota analysis, and advanced analytical techniques in the case of metabolite analysis. 
2. Phenolic Compounds in Wine 
The term “phenolic” describes those compounds that possess a benzenic ring substituted by one or 
several hydroxyl groups (−OH). Polyphenols are secondary metabolites of plants and play an important 
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role in the plant’s defense mechanism against external agents, such as animals or microbial infections, 
they facilitate pollination and seed dispersion through signals that attract insects and animals, and 
participate in protection mechanisms against ultraviolet radiation and/or oxidant agents. Phenolic 
compounds presented in grapes, located in the solid parts of the fruit (skins and seeds), have a  
wide diversity of chemical structures, including flavonoid compounds (flavan-3-ols (monomers and 
oligomeric and polymeric proanthocyanidins), anthocyanins, flavonols, and dihydroflavonols) and  
non-flavonoid compounds (hydroxybenzoic and hydroxycinnamic acids, phenolic alcohols, and 
stilbenes) (Figure 1). Although the concentration of phenolic compounds in wine is conditioned by 
several factors related to the grape (variety, soil, geography, climate, etc.) and by enological practices, 
the total polyphenol content is around 50–400 mg/L for white wines, and 900–1400 mg/L for young red 
wines. Therefore, moderate consumption of wine (250 mL/day) corresponds to an intake of 60 mg of 
polyphenols for white wines and 210 mg for young red wines [15]. With respect to their distribution by 
compound groups, acids and hydroxybenzoic derivatives represent approximately 6% of the total;  
acids and hydroxycinnamic derivatives, 1.1%; stilbenes, 0.5%; alcohols, 3.8%; flavanols, 15%;  
flavonols, 3.6%; and anthocyanins, 70% in young red wines [15]. Other anthocyanin derivatives such as 
pyranoanthocyanins present much lower proportions. 
 
Figure 1. Common phenolic compounds in wine. 
Over the last few decades, the role of polyphenols has been the focus of considerable research in the 
field of nutrition. Several epidemiological studies have shown that the intake of these compounds is 
Flavonoids
O
OH
O
OH
O
OH
Flavan -3- ols
Dimeric proanthocyanidins
O+
OH
Anthocyanins
O
OH
O
O
OH
O
Flavonols
Dihydroflavonols
Hydroxybenzoic acids
Hydroxycinnamic acids
Stilbenes
Non-Flavonoids
COOH
HO
HO
COOH
HO
Phenolic alcohols
 
Antioxidants 2015, 4 4 
 
inversely associated with the risk of various chronic diseases, such as coronary heart disease, specific 
cancers, and neurodegenerative disorders [16,17]. Indeed, potential beneficial effects have been 
demonstrated for different phenolic compounds (especially flavonoids) through in vitro assays.  
In particular, these compounds act as powerful inhibitors of low-density lipoprotein (LDL) oxidation, 
one of the main mechanisms responsible for the development of atherosclerosis. However, it is currently 
believed that the physiological activities and mechanisms of these compounds are more diverse and 
complex. Thus, phenolic compounds are able to inhibit the growth of human cancer cell lines, 
cholesterol-related processes, and the activity of enzymes, such as telomerase, lipoxygenase and 
cyclooxygenase involved in inflammatory processes [18,19]. They also interact in different signal 
transduction pathways, and can affect the cell-cycle regulation, platelet function, and prevent 
endothelium dysfunction [20,21]. 
However, the health effects of these compounds depend on their bioavailability, and therefore it is 
important to understand how they are absorbed, metabolized and eliminated from the body, in order to 
ascertain their in vivo actions. 
3. General Metabolism of Polyphenols in the Human Body 
Polyphenols are considered as xenobiotics by the human organism and therefore are extensively 
metabolized and finally eliminated, mainly in the bile but also in the urine. The first step in their 
metabolism is likely to be deglycosylation before absorption in the small intestine. Hydrolysis of some 
flavonoid glycosides might have already occurred in the oral cavity, as both saliva and oral microbiota 
show β-glucosidase activity, giving rise to the corresponding aglycones. The hydrolytic activity begins 
in the mouth, and continues through the digestive tract into the stomach, where the size of food particles 
is reduced, which prompts the release of phenolic compounds. It has been estimated that  
5%–10% of ingested polyphenols are absorbed in the small intestine, while 90%–95% reach the colon 
where they are intensively degraded by microbiota into a diversity of bioactive phenolic metabolites, 
lactones and phenolic acids that are then further absorbed [22]. 
In particular, the glycosylated polyphenols, such as anthocyanins, flavonol glycosides and glycosides 
of resveratrol, can be hydrolyzed by intestinal β-glucosidases. In contrast, monomeric flavanols, and 
dimer procyanidins can be absorbed directly into the small intestine. Once absorbed, the resulting 
aglycones would enter enterocyte by passive diffusion. Thus, the resulting aglycone is rapidly 
biotransformed by phase II enzymes into conjugated metabolites (i.e., glucuronides, O-methylethers 
and/or sulfates) within the enterocyte and again in the liver [23]. Other wine polyphenols, mainly 
oligomeric flavan-3-ols with a degree of polymerization (mDP) >3 and polymeric flavanols 
(proantocyanidins and condensed tannins), esters of hydroxycinnamic acids, and flavonols conjugated 
with rhamnose, such as rutin, are not absorbed in their native forms. These compounds reach the colon, 
where compounds are subjected to the action of the colonic microflora and transformed into various 
phenolic acids and other metabolites [24]. The methylated, glucuronide and sulfate conjugates (phase II 
metabolites) can reach the colon via enterohepatic circulation and are also susceptible to degradation by 
the intestinal microbiota. Finally, the phenolic metabolites are excreted via urine and feces. 
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4. Gut Microbiota 
The orogastrointestinal tract of humans has an abundant microbiota dominated by anaerobic  
bacteria. The number of bacteria in the oral cavity is about 1011 bacteria/g in dental plaque and  
108–109 bacteria/mL in saliva, whereas in feces the corresponding numbers are 1011–1012 bacteria/g [25]. 
More precisely, the gut microbial ecosystem includes native species that permanently colonize the 
gastrointestinal tract, and a variable number of live microorganisms that temporarily pass through the 
digestive tract [4]. Native bacteria are mainly acquired at birth and during the first year of life, whereas 
transient bacteria are continuously being ingested from food, drinks and the environment. 
Among the human gastrointestinal microbiota, the majority of the species belong to the phyla 
Firmicutes, Bacteroides, Actinobacteria and Proteobacteria [26] (Figure 2). The phylogenetic 
composition of the gut microbiota is considered specific and stable over time for each individual.  
The species vary greatly between individuals. In fact, interindividual variation in gut microbiota may, in 
part, reflect differences in dietary intake, although the response of the gut microbiota to dietary change 
can also differ among individuals. The composition of the individual’s microbiota can fluctuate under 
some circumstances, for instance acute diarrheal illnesses, antibiotic treatment, or to a lesser extent when 
being induced by dietary interventions, but the individual flora composition patterns usually remain 
constant [27]. Among the microbiota associated with the esophagus, are included microorganisms 
belonging to the genera Streptococcus, Prevotella and Veillonella, which also appear in the oral cavity. 
The density of colonization is increased about eight times from proximal regions of the small intestine 
(103 bacterias/g) until the colon. In the stomach and duodenum, the number of microorganisms is reduced 
due to acid, bile and pancreatic secretions; as advances in the small intestine, the acidity decreases due 
to the dilution of the acid, which facilitates bacterial colonization, reaching 1011 CFU (colony forming 
units)/mL in the colon. The most frequently found bacteria in this area are members of the genus 
Bacteroides, Bifidobacterium, Eubacterium, Clostridium, Lactobacillus, and Gram-positive cocci [28], 
while Enterococci and representatives of the Enterobacteriaceae family are found to a lesser extent [29]. 
Currently, there is evidence that confirms the importance of the gut microbiota in host health is 
associated to bacterial groups that colonize the intestine. The large intestine contains a complex and 
dynamic microbial ecosystem composed of commensal bacteria, potentially harmful opportunistic 
bacteria and others that can have both effects [30]. In particular, having a well-balanced gut microbiota 
composition is essential for human health. Undesirable bacteria include species of the genus Clostridium, 
Staphylococcus and Veillonella. These species can produce potentially harmful products, such as toxins 
and carcinogens, which are associated with intestinal disorders such as chronic inflammatory bowel 
diseases and other immune-related disorders. However, the use of antibiotics can disrupt the ecological 
balance and allow the overgrowth of species with potential pathogenicity, such as Clostridium difficile, 
associated with pseudomembranous colitis [31]. With regards to beneficial bacteria, among which are 
mainly included species of the genus Lactobacillus and Bifidobacterium, these play a key role in 
nutritional and disease-prevention functions, so they are used as probiotics. The main functions of these 
bacteria are: decreasing gas production, the production of short-chain fatty acids (SCFA), 
immunostimulating and antitumor activity [32,33]. 
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Figure 2. Distribution and composition of bacterial species in the gastrointestinal tract.  
CFU: colony forming units. 
Although the investigations concerning the influence of polyphenols on the gut microbiota and their 
mechanisms of action in humans are scarce, nevertheless drastic changes in fecal- and mucosa-associated 
microbiota could be related to determined diseases, such as colon cancer, short bowel syndrome and 
obesity [34]. It is important, therefore, to investigate gut microbiota composition and the influence of 
dietary intake on the human microbiome, to elucidate the implications of diet on the modulation of 
microbiota for delivering health benefits. 
The availability and feasibility of advanced methods for monitoring total bacterial communities is a 
prerequisite to be considered when designing a study to assess gut microbiota. Over recent decades, the 
introduction of culture-independent techniques like terminal restriction fragment length polymorphism 
(T-RFLP), fluorescence in situ hybridation (FISH), denaturing gradient gel electrophoresis (DGGE), and 
quantitative polymerase chain reaction (qPCR) have improved the analysis of gut microbiota. At present, 
next-generation sequencing (NGS) techniques have promoted the emergence of new, high-throughput 
technologies, such as genomics, metagenomics, transcriptomics, metatranscriptomics, etc. The 
development of these techniques has provided the opportunity to explore the taxonomic, protein-coding 
gene or expression diversity by applying more comprehensive and less biased measurements to all 
systems involved (i.e., diet, microbiota and host) [35]. However, the enormous amount of data generated 
becomes cumbersome to analyze, requiring much dedicated time as well as expertise to manage data in 
such quantity [36]. The link between high-throughput qPCR and next generation sequencing 
technologies provides manageable data with valuable quantitative and taxonomic information. NGS 
platforms involve many different technologies [37] all of which generate large, genome-scale datasets. 
Examples of current commercial platforms are the 454 (Roche), Solexa (Illumina), SOLiD and Ion 
Torrent (Life Technologies), and PacBio (Pacific Biosciences) systems. 
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5. Interaction between Wine Polyphenols and Gut Microbiota 
Taking the above-mentioned points into account, it is evident that the gut microbiome is implicated 
in the metabolism of wine polyphenols, and it also suggests that phenolic compounds and their 
metabolites may modulate the gut microbiota to a certain extent. The so-called two-way interaction 
between wine polyphenols and gut microbiota [7] can be subjected to various factors related to the 
phenolic compounds concentration and structure as well as the characteristics of bacterial strains, 
microbial environment, food matrix, etc. Prior to the specific sections about wine polyphenol metabolism 
and bacterial modulation by polyphenols, a preliminary section about experimental and analytical 
approaches used in these studies is included. 
5.1. Experimental Designs and Analytical Techniques 
5.1.1. In Vitro Gastrointestinal Tract Simulators 
Studies regarding polyphenol metabolism and microbial modulation have been carried out using 
different experimental designs, from simple approaches involving fermentation experiments in batch 
cultures and in continuous simulators, to intervention trials in animals and humans. Although in vivo 
trials are most relevant physiologically, in vitro tools have been designed to simulate intestinal conditions 
and the transformations undergone in foods during transit through the gastrointestinal tract. 
Simply, static gut models, also known as batch-type cultures, are generally closed systems using 
sealed bottles or reactors containing suspensions of fecal material, which are maintained under anaerobic 
conditions. This model approach is primarily used when assessing the stability of polyphenols in the 
presence of human-derived gut microbiota and evaluating which environmental conditions favor or limit 
polyphenol bioconversion. 
In contrast to short-duration experiments with static gut models, longer-term experiments are required 
when the adaptation of the gut microbial community to dietary polyphenols needs to be assessed. To that 
end, simulators of the gastrointestinal tract comprise stomach and small intestinal sections for the  
pre-digestion of food as well as vessels stimulating the ascending, transverse and descending sections of 
the human colon, allowing the assessment of changes in colonic areas that are very challenging to access 
in a human intervention, as well as the physiological variables (i.e., retention time, pH variations, 
gastrointestinal fluids, microbiota). 
In the past few years, dynamic in vitro gut models, such as SHIME (simulator of the human intestinal 
microbial ecosystem) (University of Ghent, Belgium) [38], the TIM-1 and TIM-2 (developed by TNO, 
Netherlands Organization for Applied Scientific Research, The Netherlands) [39] and the recent SIMGI 
(dynamic gastrointestinal tract simulator) (CIAL, CSIC-UAM, Spain), have been developed to simulate 
physiological conditions that can have an influence on the gut microbiota and their metabolic activity. 
All these systems contain different compartments representing the stomach, small intestine and colon. 
5.1.2. Analytical Approaches to the Analysis of Phenolic Microbial-Derived Metabolites 
Rapid, sensitive, and reliable analytical methods are needed for profiling microbe-derived phenolic 
metabolites in biological fluids in order to determine their contribution to the overall bioavailability of 
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polyphenols and to allow identification of biomarkers of polyphenol exposure that could be further used 
to correlate dietary intake with particular health effects, including microbial modulation. 
Gas chromatography (GC) coupled to mass spectrometry techniques (MS) and liquid chromatography 
(LC) coupled to a diode array detector (DAD), electrochemical (ECD) and, in particular, tandem mass 
spectrometry (ESI-MS/MS) are the most widely used analytical techniques for the analysis of microbial 
phenolic metabolites in biological fluids, which can be found in micromolar concentration. GC 
methodologies provide higher resolution and sensitivity than LC methodologies but a laborious sample 
preparation stage is required, since they usually involve the isolation of metabolites by liquid-liquid 
extraction (LLE) or other extraction procedures followed by further derivatization [40]. In contrast, for 
LC analysis the sample preparation step is more simple and faster and provides a very sensitive method 
for the quantification of selected phenolic metabolites when coupled to MS/MS [41]. The efficiency of 
separation and the sensitivity of LC–MS/MS methodologies can be largely improved by the use of ultra 
performance liquid chromatography (UPLC), which operates with smaller particle size (<2 μm) sorbent 
materials and at very high pressures (up to 15,000 psi). This technique coupled to MS detection is 
considered a good application in the analysis of phenolic compounds in biological fluids and food 
matrixes [41]. 
Metabolomics approaches have been used in clinical, pharmaceutical, and toxicological applications 
and have also recently emerged as fields of increasing importance in food and nutrition sciences [42]. 
The metabolome can be affected by different external and internal factors. Among them, diet is a very 
important external factor affecting the urinary metabolome because it produces notable changes in its 
composition [43]. Metabolomics studies of the polyphenols may lead to the discovery of new 
phytochemical metabolites and new biomarkers of intake that could allow the intake of dietary 
phytochemicals to be monitored, and eventually relate them to the expected biological effects [44]. 
5.2. Biotransformation of Wine Polyphenols by Gut Microbiota 
The microbial biotransformation of wine polyphenols is widely influenced by their chemical 
structure. Oligomers and polymers of flavan-3-ols are the major phenolic compounds present in the wine 
that reaches the colon. The colonic metabolism of dimeric procyanidins involves C-ring opening, 
followed by lactonization, decarboxylation, dehydroxylation, and oxidation reactions, among others [45] 
(Figure 3). In the case of galloylated monomeric flavan-3-ols, the microbial metabolism usually starts 
with the rapid cleavage of the gallic acid ester moiety by microbial esterases, giving rise to gallic acid 
which is further decarboxylated into pyrogallol. The C-ring is subsequently opened, giving rise to  
1-(3′,4′-dihydroxyphenyl)-3-(2″,4″,6″-trihydroxyphenyl)-propan-2-ol, which is later converted into  
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone in the case of (epi)catechin or 5-(3′,4′,5′-trihydroxyphenyl)-
γ-valerolactone in the case of (epi)gallocatechin. The valerolactone ring later breaks, giving rise to  
5-(3′,4′-dihydroxyphenyl)valeric acid and/or 4-hydroxy-5-(3′,4′-dihydroxyphenyl) valeric acid. 
Subsequent biotransformations of these valeric acids give rise to hydroxyphenylpropionic and 
hydroxybenzoic acids by successive loss of carbon atoms from the side chain through β-oxidation 
(Figure 3). 
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Figure 3. Catabolism of monomeric flavan-3-ols by gut microbiota. 
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With regard to microbial catabolism of flavonols, other flavonoid compounds present in the wine are 
directly transformed into 3,4- or 3,5-dihydroxylated phenylacetic acids [46]. In the case of anthocyanins, 
they are converted into 3,4-dihydroxy-, 4-hydroxy-, 3,4-dimethoxy- or 3-methoxyl-4-hydroxyl benzoic 
acids according to the substitution pattern of the B-ring of the precursor anthocyanin molecule [46]. 
However, in spite of the fact that anthocyanins are abundant in wine, their circulating levels in plasma 
are very low, which has been attributed to anthocyanin instability under neutral pH [47], their extensive 
metabolism in vivo [48], and their probable catabolism by intestinal microbiota [5]. Thus, it has been 
described that less than 1% of the ingested anthocyanins are typically absorbed and excreted in the  
urine [49], which might be found in low concentrations in serum, feces, urine (in the nanomolar 
concentrations) [50]. 
In the case of non-flavonoid compounds present in wine, hydroxycinnamic esters (i.e., caffeic acid 
derivatives) are mainly transformed into 3-hydroxyphenylpropionic acid, benzoic acid and 4-ethylcatechol. 
Once absorbed, the microbial metabolites are mainly metabolized in the liver by phase II enzymes as 
conjugated metabolites (glucuronides and sulfates). Other reactions that can take place are glycination, 
dehydrogenation, hydroxylation and methylation. In fact, different studies have proved the presence of 
phase II and microbial-derived phenolic metabolites in plasma and urine after ingestion of wine and wine 
polyphenols (see for review [51,52]). Some previous studies have confirmed that a moderate intake of 
red wine effectively led to a significant increase of phenolic metabolites in human feces [53,54]. 
Despite the advances recently made in the knowledge of the identification of phenolic metabolites, 
the specific bacterial species able to metabolize most wine polyphenols in the gastrointestinal tract and 
the anaerobic degradation pathways have still not been identified. So far, only a few bacterial species, 
some of them belonging to the class Clostridiales, such as Eubacterium sp. and Flavonifractor sp., and 
Eggerthella spp., have been reported to be able to initiate the metabolism of flavanol-3-ols [55–57]. 
5.3. Modulation of Gut Microbiota by Wine 
Tables 1 and 2 report different studies of modulation of gut microbiota by wine and grape polyphenols 
using different experimental approaches: batch culture fermentations, human gastrointestinal simulators, 
animal model studies and human interventions. For all of them, details about experimental conditions 
and/or study design, microbial techniques used and main effects on bacteria groups (growth 
enhancement, growth inhibition or no effect) are included. 
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Table 1. Studies regarding modulation of gut microbiota by wine polyphenols using batch culture fermentations and gastrointestinal  
tract simulator. 
Studies Using Batch Culture Fermentation 
Reference 
Fecal 
Concentration 
Phenolic 
Compound/Food 
Dose 
Time of 
Incubation 
Microbial Technique Growth Enhancement Growth Inhibition No Effect 
[58] 10%, w/v (+)-Catechin 
150 mg/L,  
1000 mg/L 
<48 h FISH 
Lactobacillus–Enterococcus spp.; 
Bifidobacterium spp.;  
C. coccoides–E. Rectale group  
E. coli 
C. histolyticum group  
[59] 10%, w/v 
Malvidin-3-O-glucoside 
Anthocyanidins mixture 
20 mg/L and  
200 mg/L 
4850 mg/L and 
48,500 mg/L 
<24 h FISH 
Lactobacillus–Enterococcus spp.; 
Bifidobacterium spp.;  
C. coccoides–E. rectale group 
  
[60] 10%, w/v 
Grape seed  
extract fractions 
300–450 mg/L <48 h FISH Lactobacillus–Enterococcus spp. C. histolyticum group  
[61] 1% w/v Red wine extract 600 mg/L 48 h FISH  C. histolyticum group 
Lactobacillus–
Enterococcus spp. 
[62]  Red wine extract 500 mg/L 48 h qPCR 
Lactobacillus spp.;  
Bifidobacterium spp.;  
Bacteroides spp.;  
Ruminococcus spp. 
  
[63] 20% w/v 
Red wine/ 
grape extract 
500–1000 mg/L 72 h HITChip    
Studies Using a Gastrointestinal Simulator 
Reference Simulator 
Phenolic 
Compound/Food 
Dose Time Microbial Technique Population Increase Population Decrease No Effect 
[64] Twin-SHIME Red wine-grape extract 
3 × daily dosing 
(1000 mg 
polyphenols as 
total daily dose) 
2 weeks 
Plate count qPCR PCR-
DGGE; Pyrosequencing 
Klebsiella spp.; Alistipes spp.; 
Cloacibacillus spp.;  
Victivallis spp.;  
Akkermansia spp. 
Bifidobacteria; Blautia 
coccoides group; 
Anaeroglobus spp.; 
Subdoligranulum spp. 
Bacteroides 
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Table 2. Studies regarding modulation of gut microbiota by wine polyphenols in studies with animals and humans. 
Animal Model Studies 
Reference Simulator 
Phenolic 
Compound/Food 
Dose Time Microbial Technique Population Increase Population Decrease No Effect 
[65] Rats 
Red wine 
polyphenols 
powder 
50 mg/kg 16 weeks Plate count Lactobacilli; Bifidobacteria 
Propionibacteria; 
Bacteroides; Clostridia 
 
[66] 
Broiler 
chicks 
Grape seed 
extract (GSE) 
7.2 g/kg diet 
(GSE)  
(free access) 
21 days 
Plate count  
T-RFLP 
E. coli; Enterococcus spp.; 
Lactobacillus spp. 
  
[67] Pigs 
Grape seed 
extract 
1% (free access) 4 weeks qPCR  
Streptococcus spp.; 
Clostridium Cluster XIVa 
Lactobacillus spp; 
Bifidobacterium spp. 
[68] Pigs 
Grape seed 
extract 
1% w/w 6 days 
Ilumina MiSeq 
platform 
Lachnospiraceae, Clostridales, 
Lactobacillu, Ruminococcacceae 
  
Human Intervention Studies 
Reference 
Volunteer 
Numbers 
Phenolic 
Compound/Food 
Dose 
Treatment 
Duration 
Microbial Technique Population Increase Population Decrease No Effect 
[69] 9 
Proantocyanidin-
rich extract from 
grape seeds 
0.5 g/day 6 weeks Plate count Bifidobacterium spp. Enterobacteriaceae  
[70] 10 Red wine 272 mL/day 20 days qPCR 
Enterococcus spp.;  
Prevotella spp.;  
Bacteroides Bifidobacterium spp.; 
Bacteroides uniformis 
Eggerthella lenta Blautia 
coccoides–E. rectale group 
Clostridium spp.;  
C. histolyticum group 
Actinobacteria 
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5.3.1. Studies Using Batch Culture Fermentations 
One of the first relevant experiments using batch culture fermentation and a standard compound present 
in grape seeds and wine was carried out by Tzounis et al. [58] who found that the flavan-3-ol monomers 
((−)-epicatechin and (+)-catechin) promoted the growth of the Clostridium coccoides–Eubacterium rectale 
group, which is known to produce large amounts of butyrate, a short-chain fatty acid (SCFA) with  
anti-inflammatory and antineoplastic properties (Table 1). Compared to (−)-epicatechin, (+)-catechin 
exposure resulted in a greater modification of the growth of the bacterial groups; (+)-catechin also 
increased the growth of Lactobacillus–Enterococcus spp., Bifidobacterium spp. and Escherichia coli but 
decreased the growth of Clostridium histolyticum. In contrast, the effect of (−)-epicatechin only 
significantly increased the growth of the C. coccoides–E. rectale group. Also using standard compounds 
of anthocyanins (i.e., malvidin-3-glucoside and a mixture of anthocyanins), Hidalgo et al. [59] found a 
significant increase in the growth of Lactobacillus–Enterococcus spp. and Bifidobacterium spp. 
Recently, our research group carried out several batch culture fermentations of two flavan-3-ol 
fractions with different degrees of polymerization from grape seed extract and of wine polyphenols, with 
fecal microbiota from three healthy volunteers [60,61]. Both flavan-3-ol fractions induced the growth of 
Lactobacillus/Enterococcus spp. and inhibited the C. histolyticum group during fermentation, although 
the effects were only statistically significant with the less polymerized fraction. However, wine 
polyphenols only showed a slight inhibition in the C. histolyticum group, probably due to their lower 
content in flavan-3-ols and the time of exposure. Additionally, this type of fermentation has also been 
used to assess the contribution of certain probiotic strains to the colonic metabolism of polyphenols. 
With this in mind, Barroso et al. [62] carried out fermentations of a red wine extract inoculated with 
human microbiota obtained from the colonic compartments of a dynamic simulator, in the presence and 
absence of the probiotic strain Lactobacillus plantarum IFPL935. Microbial analysis by qPCR indicated 
that red wine polyphenols induced greater variations among in vitro batches harboring different  
colon-region (ascending colon, descending colon and effluent) microbiota than those found when  
L. plantarum IFPL935 was added. Batches inoculated with microbiota from the ascending colon were 
shown to harbor the major proportion of saccharolytic bacteria (Bacteroides, Bifidobacterium, Prevotella) 
whereas Clostridium groups were found in major numbers in the batches inoculated with microbiota 
simulating the distal regions [62]. 
Gross et al. [63] carried out in vitro fermentation of a red wine/grape and black tea polyphenols with 
fecal samples from 10 human volunteers. Microbial composition of fecal samples using HITChip 
analysis indicated different bacterial populations present in the individual fecal microbial communities. 
This inter-individual variability was related to the production of different metabolites, suggesting that 
each individual generates a specific microbial metabolome. 
5.3.2. Studies Using Human Gastrointestinal Simulators 
As an example of the versatility and potential of human gastrointestinal simulators, Table 1 also 
reports a study concerning the modulation of gut microbiota by polyphenols using the SHIME [38].  
This validated model comprises stomach and small intestinal sections for predigestion of food as well as 
vessels stimulating the ascending, transverse and descending parts of the human colon, allowing 
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assessment of changes in the different colonic areas that are very challenging to access in a  
human intervention. 
The use of the twin-SHIME to investigate the effects of a red wine extract on the colonic microbiota 
was the aim of a study recently carried out by Kemperman et al. [64]. These authors characterized 
microbial community changes using a combination of analyses including cultivation, PCR-denaturing 
gradient gel electrophoresis (DGGE), quantitative PCR and high-throughput pyrosequencing of the 16S 
ribosomal RNA gene. They observed that the continuous administration of red wine extracts for  
two weeks could modulate select members of the human gut microbiota, revealing novel targets 
potentially involved in polyphenol metabolism and/or resistant microbes. 
5.3.3. Animal Model Studies 
It is widely known that preliminary evidence should be warranted in animal models before human 
intervention trials. Animal models contribute to a better understanding of the mechanisms and biological 
effects that could be likely to happen in the human body. Caution is required in extrapolating results to 
humans because culture-independent comparisons have revealed that most bacterial genera and species 
found in mice are not seen in humans, although the distal gut microbiota of mice and humans harbor the 
same bacterial phyla. Nevertheless, the use of germ-free mice inoculated with human fecal microbiota 
is of great relevance. Such humanized mice provide a model system for controlling host genotype, gut 
microbiota composition, diet, and housing conditions. To date, no studies have followed the composition 
of the intestinal microbiota in humanized rodents fed a diet rich in wine polyphenols [71]. 
In this section, studies performed on animals in order to assess the effects of wine polyphenols on the 
modulation of intestinal microbiota are summarized (Table 2). 
Dolara et al. [65] showed that treatment with wine polyphenols in carcinogen-treated F344 rats was 
associated with a strong variation in the colonic microbiota, compared to the control-fed rats.  
Although the total bacterial counts and anaerobe/aerobe ratio of microorganisms in the feces from 
polyphenol-treated rats were similar to those from control rats, Propionibacteria, Bacteroides and 
Clostridia decreased while Lactobacilli and Bifidobacteria increased. Based on additional experiments, 
these authors concluded that reduction of oxidative damage, modulation of colonic flora and variation 
in gene expression may all be connected in the action of wine polyphenols on the intestinal function  
and carcinogenesis. 
Another animal experiment was conducted to study the effect of the inclusion of grape seed extracts 
in the diet of broiler chicks [66] on intestinal microbiota. It was observed that, for the cecum, birds fed 
grape extracts had higher populations of E. coli, and Lactobacillus and Enterococcus species than birds 
in control groups. These authors concluded that polyphenol-rich grape products modified the gut 
morphology and intestinal microbiota and increased the degree of biodiversity in intestinal bacteria of 
broiler chicks. 
Animal studies performed in pigs [67,68] demonstrated that grape seed extract administration caused 
an ecological shift in the microbiome. Thus, the administration of grape seed extracts produced lower 
counts of Streptococcus spp and Clostridium cluster XIVa [67], and increased Lachnospiraceae, 
Clostridales, Lactobacillus and Ruminococcus during the intervention period [68]. 
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5.3.4. Human Intervention Studies 
Investigations carried out with humans potentially provide the best models for studying the 
interactions of food components (e.g., polyphenols) with microbiota, although in vivo intervention trials 
hold inevitable practical and ethical limitations [8]. The use of crossover designs, where volunteers serve 
as their own control, permit multilevel analysis schemes that increase power, but as with other human 
intervention studies, they require a relevant number of volunteers to allow for statistically significant 
multivariate models [72]. Up to now, only a few studies have examined the in vivo impact of dietary 
polyphenols on the human gut microbiota, and most of them were focused on single polyphenol 
molecules and selected bacterial populations (Table 2). 
In a study with a reduced number of subjects (n = 9), Yamakoski et al. [69] reported that 
administration of a proanthocyanidin-rich extract from grape seed significantly increased the fecal 
number of Bifidobacterium spp., whereas a reduction in the level of putrefactive bacteria, such as 
Enterobacteriaceae was observed. 
Queipo-Ortuño et al. [70] performed a randomized, crossover and controlled trial (n = 10), which 
studied the effect of the intake of red wine, de-alcoholized red wine and gin over three consecutive 
periods. After the red wine period, the bacterial concentrations of Proteobacteria, Fusobacteria, 
Firmicutes and Bacterioidetes markedly increased compared with the washout period; significant 
increases in the number of Bifidobacterium spp. and Prevotella spp. were also observed. In contrast, 
Clostridium spp. and C. histolyticum group concentrations decreased after the red wine period. 
6. Conclusions 
Assessment of microbial metabolism of wine polyphenols is necessary to clarify the potential 
physiological effects on human health associated with moderate consumption of wine. There is scientific 
evidence that polyphenols may contribute to the maintenance of gut health by the modulation of the gut 
microbial balance through the stimulation of the growth of beneficial bacteria and the inhibition of 
pathogen bacteria, exerting prebiotic-like effects. Although genetic and environmental factors are the 
main determinants of gut microbiota composition, it is well established that diet influences microbial 
fermentation and total bacteria in the intestine. In fact, inter-individual variation in gut microbiota may, 
in part, reflect differences in dietary intake, although the response of the gut microbiota to dietary change 
can also differ among individuals. Therefore, the availability of advanced methods for monitoring 
bacterial communities could provide a better understanding of the underlying mechanisms in the 
polyphenols–microbiota–host triangle, and elucidate the implications of polyphenols on host health. 
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